Boston Scientific (BSX)

• Market cap: $146B
• 1 day: -0.27%
• 5 days: -5.33%
• 1 month: -4.68%
• 3 months: -3.1%
• 6 months: -1%
• Year to date: 9.9%
• 1 year: 18.97%
• 5 years: 155.28%
• 10 years: 486.45%
• Sector: Healthcare
• Industry: Medical Devices

About: Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.

Employees: 53,000

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

76% more first-time investments, than exits

New positions opened: 151 | Existing positions closed: 86

38% more repeat investments, than reductions

Existing positions increased: 743 | Existing positions reduced: 540

26% more call options, than puts

Call options by funds: $1.08B | Put options by funds: $859M

9% more capital invested

Capital invested by funds: $133B [Q1] → $145B (+$11.9B) [Q2]

3% more funds holding

Funds holding: 1,620 [Q1] → 1,661 (+41) [Q2]

2.05% more ownership

Funds ownership: 89.01% [Q1] → 91.06% (+2.05%) [Q2]

20% less funds holding in top 10

Funds holding in top 10: 50 [Q1] → 40 (-10) [Q2]

Research analyst outlook

8 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $121
• Avg. target: $126
• High target: $135

8 analyst ratings

• positive: 8 100%
• neutral: 0 0%
• negative: 0 0%

Needham Mike Matson	$121	Buy Reiterated	11 Sep 2025
Oppenheimer Steven Lichtman	$125	Outperform Upgraded	8 Sep 2025
UBS Danielle Antalffy	$135	Buy Maintained	24 Jul 2025
Raymond James Jayson Bedford	$124	Strong Buy Maintained	24 Jul 2025
Wells Fargo Larry Biegelsen	$124	Overweight Maintained	24 Jul 2025